Company Overview: Onconova

Industry News

15 May

Investor Network: Onconova Therapeutics Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 15, 2017 / Onconova Therapeutics Inc. (NASDAQ: ONTX) will be discussing their earnings results in their Q1 Earnings Call to be held 5/15/2017 at 9:00 AM Eastern Time. To listen to the event live – visit https://www.investornetwork.com/company/22398. Replay Information The replay will...

Read more

27 Apr

Onconova Therapeutics Announces Closing of Public Offering of Common Stock

NEWTOWN, Pa., April 26, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced the closing of its previously announced public offering of...

Read more

21 Apr

Onconova Therapeutics Announces Pricing of Public Offering of Common Stock

NEWTOWN, Pa., April 21, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS) today announced that it has priced an underwritten public offering of...

Read more

4 Apr

Onconova Therapeutics Announces Positive Preclinical Data for Third-Generation Oral CDK4/6 + ARK5 Inhibitor and dual FLT3 and Src inhibitor at 2017 American Association of Cancer Research (AACR) Annual Meeting

NEWTOWN, Pa., April 04, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes, announced promising pre-clinical data for first-in-class dual inhibitor of CDK4/6 + ARK5,...

Read more

Page 1 of 512345

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address